NCT02182245 2025-01-23
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
Boehringer Ingelheim
Phase 1 Completed
Boehringer Ingelheim
Opna Bio LLC
Belgian Gynaecological Oncology Group
M.D. Anderson Cancer Center
Eli Lilly and Company